Mohamed Salem, MD
Medical Oncology · Charlotte, NCNPI 1497882369
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $252,017 of the $395,624 with a category attached, or 63.7%. 15 manufacturers reported payments, led by AstraZeneca at 35.6% of the total. Reporting peaked in 2023 at $152,611 and has fallen 86.2% since, to $21,013 in 2025. Among medical oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $1177.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$141K
- Taiho Oncology, Inc.$87K
- E.r. Squibb & Sons, L.L.C.$76K
- Seagen Inc.$23K
- Array Biopharma Inc$16K
- Daiichi Sankyo Inc.$14K
- plus $39K from 9 others
Across 27 payments — averaging $9708.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$235K
- Seagen Inc.$27K
- Merck$221
What the payments were for
- Consulting fees$85,40822%
- Speaking & faculty fees$252,01764%
- Travel & lodging$51,88513%
- Food & beverage$6,3152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 92 | $140,831 |
| Taiho Oncology, Inc. | 97 | $86,730 |
| E.r. Squibb & Sons, L.L.C. | 54 | $75,734 |
| Seagen Inc. | 19 | $22,516 |
| Array Biopharma Inc | 13 | $16,266 |
| Daiichi Sankyo Inc. | 7 | $14,313 |
| Exelixis Inc. | 23 | $10,727 |
| Pfizer | 12 | $10,283 |
| Incyte Corporation | 12 | $7,355 |
| Amgen | 2 | $3,245 |
| Beone Medicines USA, Inc. | 1 | $2,400 |
| Blueprint Medicines Corporation | 1 | $1,890 |
| Novartis | 1 | $1,875 |
| Merck | 1 | $1,350 |
| Genentech USA, Inc. | 1 | $108 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$395,624 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 11 | $5,627 |
| Prochlorperazine Maleate | 45 | $404 |
| Ondansetron Hcl | 35 | $357 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Charlotte
- David RizzieriCharlotte$714K
- Nilanjan GhoshCharlotte$510K
- Edward KimCharlotte$188K
- Kathryn MilehamCharlotte$110K
- Antoinette TanCharlotte$89K
- Jimmy HwangCharlotte$64K
- Ashley SumrallCharlotte$55K
- Obiageli OgbataCharlotte$26K
- Daniel CarrizosaCharlotte$20K
- Daniel HaggstromCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.